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Managing the immediate demands of the current COVID-19 global pandemic has 
tested many healthcare systems across the world, to their limits. As we move 
forward, new challenges due the impact of this must be faced. The rapidity of spread
appears to be slowing, the curve may be flattening, and cautiously, whilst alert to the 
risk of a ‘second wave’, the international healthcare community has started to 
acknowledge the need to develop strategies to address the ongoing needs of those 
most significantly affected by the pandemic. Globally critical care survival following 
COVID-19 infection is estimated at between 16-37%, although many cohorts include 
those receiving ongoing care in ICU. 1-4 The number of infections reported worldwide 
is in the many millions, and increases on a daily basis, 5 heralding a cohort of 
critically ill survivors of unprecedented size.
The treatment needs of COVID-19 survivors are not yet fully understood. Although 
initially assumed to be a respiratory disease, it is now clear that it affects a variety of 
systems. Multi-organ failure can occur, with reports of cardiac, renal, haematological 
and neurological effects in the acute stages. It is likely therefore, that these survivors
will have significant multi-domain impairment requiring ongoing support. There has 
been a recent ‘call to action’ amongst the rehabilitation community to act quickly to 
ensure adequate resources to provide early phase, multidisciplinary interventions to 
promote physical and psychological recovery.6 It is therefore timely to highlight the 
potential risk of chronic pain associated with COVID-19 infection, explore the 
challenges of pain management in this cohort and identify opportunities to improve 
clinical services, as well as  the evidence base on the consequences of not only 
SARS-CoV-2 infection, but critical illness survivors more generally.
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We can perhaps learn from previous studies of critical care survivorship, which has 
been relatively neglected until recently.  This complex challenge has been termed 
‘post-intensive care syndrome’(PICS). 7 It incorporates the cognitive, physical and 
psychological dysfunction reported following ICU discharge that can have profound 
effects on quality of life. Chronic pain is often part of this, but how this additional co-
morbidity affects critical care survivors is poorly understood. Estimates of chronic 
pain prevalence following ICU vary from 14-77% depending on timescale, method of 
measurement and population.8 Pain also appears to be an important factor affecting 
ability to return to work and quality of life, up to 5 years post discharge.9 Therefore 
there is a real need to gain clarification on how to manage pain in these patients – 
perhaps those surviving critical illness with COVID-19, who may be  at particular risk 
of developing chronic pain, present an opportunity for clinicians to understand more 
about the development and management of pain following critical illness and to 
initiate best practice that could continue as a positive legacy of the pandemic. There 
are a number of reasons why this may be the case, as outlined in Figure 1.
As one consistent risk factor for chronic pain development is the occurrence of acute
pain, it is worth considering how this is managed in ICU. Those recalling higher pain 
and distress during ICU admission appear to be at higher risk of developing chronic 
pain after discharge.10 Unfortunately, even in ‘peace time’ on ICU, pain management 
is problematic and evidence suggests a high proportion of those on critical care 
experience moderate to severe pain for prolonged periods.11 Barriers to high quality 
pain management in ICU are multifactorial but appear to stem from a limited 
evidence base for best practice, the challenges of patient-clinician communication of 
symptoms, for example in those that are intubated, sedated or cognitively impaired, 
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pressures on staffing and workload, and from a lack of focus of education in the 
area.  Guidelines to improve pain assessment and management in ICU have been 
developed in the US and Europe, and initiatives such as the ICU Liberation 
‘ABCDEF bundles’ of care have been adopted in some centres. These are aimed at 
improving long term outcomes through multidisciplinary management of symptoms, 
mobility and communication.12,13 
However, these processes, which often involve non-pharmacological strategies, are 
labour intensive and realistically may be unachievable in current pandemic 
conditions. Furthermore, during this outbreak, in many countries the ICU workforce 
has been stretched to beyond its capacity with patients being treated, through 
necessity, by staff with rapidly scaled-up training in units with reduced staffing 
ratios.14 There is therefore the potential that detailed attention to non-lifesaving 
symptomatic control, that would be desirable in optimal circumstances, is not 
possible, with an increase in barriers to providing effective analgesia.. The critically ill
undergo a significant pain burden during everyday procedures in ICU, such as 
endotracheal tube suctioning, turning, positioning and line insertion.15 Due to the 
severity of COVID-19 critical illness it is likely that survivors will have undergone 
multiple pain associated interventions during their admission. 
COVID-19 survivors are likely to have sustained a prolonged period of 
immobilisation, sedation and ventilation,4 putting them at high risk of associated ICU-
acquired weakness. Commonly manifesting as any combination of critical illness 
myopathy, critical illness polyneuropathy and muscle atrophy, known risk factors 
include the use of neuromuscular blockade and corticosteroids, the presence of 
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sepsis and multiorgan dysfunction as well as prolonged mechanical ventilation.16 
Neuromuscular blockade is now highlighted in several guideline publications as a 
strategy to improve ventilation in those with ARDS associated with COVID-19;17,18 
although there is no consensus, some recommendations also include the use of 
corticosteroids in certain populations.19 The prevalence of ICU acquired weakness in 
the general ARDS population is estimated at between 25-96% and although reported
following the Middle East Respiratory Syndrome (MERS) epidemic, is yet to be 
determined in those critically ill with COVID-19.20,21 Whilst the focus of ICU acquired 
weakness is often the motor component, there is growing evidence for sensory 
disruption and associated pain. Weakness can lead to rapid deconditioning, joint 
related pain and contractures and, although mechanisms remain unclear, shoulder 
pain in particular has been highlighted as a significant problem in the post ICU 
population.22 
A mainstay of respiratory support through the pandemic has been the use of 
repeated patient proning to improve ventilation.17-19 However, complications 
associated with proning sedated patients include brachial plexopathy, joint 
subluxation and soft tissue damage, that have the potential to result in persistent 
neuropathic and musculoskeletal pain.23 The longer-term consequences of such 
strategies need to be carefully monitored.
Neuropathic symptoms including numbness, paraesthesia and pain are well 
documented following critical illness with abnormalities in nerve conduction studies 
demonstrated up to 5 years following ICU discharge.24 Even in the absence of 
electrophysiological abnormalities, small nerve fibre impairment associated with 
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neuropathic symptoms can persist for several months.25 Understanding more about 
sensory dysfunction could provide a great deal of insight into the pathophysiology of 
chronic pain after critical illness and allow for the development of strategies to both 
prevent and treat pain in a cohort where evidence is limited.
Reports of neurological sequelae of COVID-19 infection are emerging, indicating 
both central and peripheral nervous system involvement - symptoms such as 
confusion, headache and dizziness, as well as anosmia, ageusia and nerve pain are 
now described in retrospective cohorts and case reports.26 This has led to 
speculation of potential neurotropism, with both muscle and neural tissue expressing
Angiotensin Converting Enzyme (ACE) 2 receptor, the implicated functional receptor 
for SARS-CoV-2.27 The related SARS-CoV virus is also associated with neural injury,
including axonopathic polyneuropathy, and has been detected in both the CSF and 
brain tissue.28,29 There are ongoing efforts to determine which human cells are 
susceptible to SARS-CoV-2 infection but direct neural invasion has not yet been 
definitively established.30 
Regardless of direct neural entry, SARS-CoV-2, like SARS and MERS, appears to 
have the capacity to induce painful para-infectious neurological disease as 
demonstrated by a growing number of case reports of Guillan Barre syndrome and 
polyneuritis).31,32 Thrombotic, hypotensive and hypoxic consequences of infection 
can also contribute to longstanding, potentially painful neurological sequelae such as
stroke. Renal dysfunction is also common and may be associated with a peripheral 
neuropathy, particularly if renal impairment persists after the acute injury. A further 
aspect to consider is neuropathic pain as a side effect of putative therapeutic agents 
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currently under investigation for modifying disease severity, such as 
lopinavir/ritonavir and hydroxychloroquine. 
It is now clear that COVID-19 infection itself is associated with painful symptoms, 
including myalgia, arthralgia, abdominal pain, headache and chest pain and even 
those not admitted to critical care environments may require have pain, requiring 
opioids for symptom management.33 
An important area to recognise is the psychological impact of COVID-19, with the 
unique social restrictions likely to create an additional burden. Severe psychological 
sequelae have been demonstrated in ICU survivors with up to 30% of ARDS 
survivors developing PTSD.34 In COVID-19 this may be augmented by separation 
from family, use of personal protective equipment (PPE) adding to the already alien 
environment, breakdown of social networks and fear of mortality with the potential for
development of PTSD, anxiety and depression, as was observed in the SARS 
outbreak.35 Pain is thought to have a bidirectional relationship with such 
psychological factors: in the acute phase, it may be a risk factor, contributing to the 
development of mental health co-morbidities, with chronic pain being a well-
recognised co-morbidity.
Even baseline patient characteristics, identified as factors associated with the 
development of severe COVID-19 illness, overlap with those associated with chronic 
pain after critical illness, including multi-morbidity and increasing age.36 It is also 
likely that those with pre-existing multi-morbidity were at higher risk of chronic pain 
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prior to infection which may predispose them to exacerbation of current or 
development of new pain conditions.37 
Emerging reports from Wuhan, which is now operating several rehabilitation 
institutions for COVID-19 survivors, and Italy, indicate a significant symptom burden 
in COVID-19 survivors including anxiety, sleep disorders, fatigue, limited exercise 
tolerance as well as memory and executive function impairment.38 Such symptoms 
are likely to be exacerbated or even attributed to pain although this is yet to be 
explored. What remains unclear is the level of rehabilitation that will be possible for 
different countries in the early phase of recovery. Early intervention including 
adequate pain management, psychological and physical therapy has the potential to 
reduce the risk of long-term pain as well as other features of PICS.39 However, 
currently resources are focused on frontline services which may leave limited 
support for an unprecedented cohort of patients. 
There is conflicting evidence on the beneficial effects of post ICU rehabilitation 
strategies in general on exercise tolerance and health related quality of life in the 
pre-COVID era, however qualitative evaluation suggests increased patient 
satisfaction and reduced anxiety.40,41 Although pain forms a component of health-
related quality of life measures, specific research into the effect of post ICU 
rehabilitation on pain has never been formally evaluated. The majority of studies on 
efficacy of pain management and post-critical illness rehabilitation have focused on 
face to face delivery, often in a group-based setting. Such traditional models of care 
may not be possible for some time, with ongoing social distancing and diversion of 
healthcare resources. We therefore need to develop and assess innovative ways to 
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deliver therapy that is accessible to those who need it. Telemedicine and promotion 
of self-management programmes are being explored for this cohort and in the future 
may be part of the ‘new normal’ for delivery of this type of service, yet for some 
vulnerable patient groups (e.g. elderly, cognitively impaired, high deprivation) access
may be problematic.
Stratifying patients to high intensity or speciality specific rehabilitation through a 
stepped care model may be required but is difficult given the lack of specific COVID-
19 research and experience, yet extrapolation of best practice evidence from other 
cohorts will be required.  Historically, rehabilitation for survivors of critical illness has 
been disease specific, for example: cardiac patients may get streamed to a cardiac 
rehabilitation pathway; those with chronic respiratory disease to pulmonary 
rehabilitation; those with a stroke to post-stroke resources. However this was 
problematic for two reasons; firstly, these classes and pathways were not designed 
to address the additional burden of PICS in addition to the patients underlying 
condition and secondly, there was a large proportion of patients that did not fall into 
these categories, whom ‘slipped through the net’ and received suboptimal care.
Several models of more contemporary general ICU follow-up clinics currently exist 
but they are by no means universal and it is likely that these have not been subject 
to the number of patients that will need their services in the foreseeable future.42 The 
make-up of such services may also need to be adjusted to address COVID-19 
specific sequelae and this may represent an opportunity to develop better links 
between pain and ICU survivorship programmes, as well as improving dialogue with 
other specialties such as renal, respiratory and mental health to build existing 
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collaborations and manage multi-morbidity. Pain services are traditionally 
multidisciplinary, incorporating physical and psychological expertise with the goal of 
improving function and quality of life and could therefore have a great deal to offer 
overwhelmed critical care services. However, pain services in many countries are 
already under-resourced and overwhelmed by patient need therefore there is likely 
to be variation in the ability of services to respond to this need. Nonetheless, 
integrated follow up pathways which include pain could provide an opportunity to 
develop embedded research and registries to learn more about the features, 
aetiology, risk factors and therapeutic interventions for chronic pain following critical 
illness, an as yet neglected area of critical care survivorship.
In the rapidly changing clinical environment we are working in now, flexibility and 
changes to health and social care delivery are required. Whilst the trajectory of this 
pandemic has not given us the luxury of developing a high-quality evidence base on 
which to base our management decisions, it is beholden on us to critically assess 
what we are doing. Perhaps now more than ever, we need to work collaboratively to 
robustly assess interventions used in rehabilitation of post COVID-19 patients. There
is the opportunity to use a similar approach to that of some clinical trials of acute 
interventions (such as RECOVERY (https://www.recoverytrial.net/)), where adaptive 
trial design allows rapid evaluation of a range of potential COVID-19 treatments. 
Although the acute challenges of managing COVID-19 have been significant,  it may 
be the long term effects, including pain, that will have the greatest impact on 
individuals and society, As an academic community, understanding post COVID  
effects and ensuring a strong evidence base for how to manage these is vital for 
patients, health and social care systems, and policy makers. 
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Figure Legends
Figure 1. Potential risk factors for the development of chronic pain following COVID-
19 infection. (PTSD=post-traumatic stress disorder)
